← Back
Data updated: Mar 10, 2026
CARNEGIE
OncologyGastroenterologyDermatology
CARNEGIE is a generic drug manufacturer focused on Oncology, Gastroenterology, Dermatology.
1965
Since
14
Drugs
-
Trials
77
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
LOMUSTINE 2025-10-27
LETROZOLE 2025-10-24
Labeling
ETRAVIRINE 2025-10-02
LETROZOLE 2025-10-01
Labeling
LETROZOLE 2025-10-01
Labeling
ERYTHROMYCIN 2025-09-23
PRIMIDONE 2025-09-23
Labeling
AMINOCAPROIC ACID 2025-08-28
CLINDAMYCIN PHOSPHATE 2025-08-22
Labeling
CLINDAMYCIN PHOSPHATE 2025-08-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 20%
2 drugs
Gastroenterology 20%
2 drugs
Dermatology 20%
2 drugs
Neurology 20%
2 drugs
Immunology 20%
2 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Dermatology, Immunology, Gastroenterology
Eli Lilly big-pharma
Oncology, Immunology, Neurology, Dermatology
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Neurology
Takeda big-pharma
Immunology, Oncology, Gastroenterology, Neurology
AbbVie big-pharma
Immunology, Oncology, Neurology
Active (8)
Discontinued (6)
Company Info
- First Approval
- 1965-04-02
- Latest
- 2025-10-27
- Applications
- 13